# US 2024/0189279 A1 · Immunomodulatory compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189279 A1
- Document ID: US20240189279A1
- Status: Published application
- Kind: A1
- Application number: 18/536,002
- Filed: 2023-12-11
- Published: 2024-06-13
- Earliest claimed: 2022-12-11
- Assignees: The Texas A&M University System; Trustees of Tufts College
- Applicants: The Texas A&M University System; Trustees of Tufts College
- Inventors: Arul Jayaraman; Kyongbum Lee
- Web page: https://patentgrep.com/patent/US20240189279A1

## CPC

- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided here are immunomodulatory compositions for and methods of treatment of inflammation-associated diseases, such as liver disorders and acute respiratory distress syndrome (ARDS). The composition can be a tryptophan metabolite, such as indole 3-acetate, tryptamine, xanthurenic acid, or a derivative of any thereof. The methods can include administering the subject a therapeutically effective amount of the immunomodulatory composition provided herein. The liver disorders can be non-alcoholic fatty liver disease, steatosis, non-alcoholic steatohepatitis, and/or fibrosis. The ARDS can be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

## Claims

### Claim 1

A method of treating a liver disorder, the method comprising administering to a human subject with a liver disorder a therapeutically effective amount of a composition containing a tryptophan metabolite or a derivative thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tryptophan metabolite contains indole 3-acetate or a derivative thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tryptophan metabolite contains tryptamine or a derivative thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tryptophan metabolite contains xanthurenic acid or a derivative thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the liver disorder is non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, steatosis, and/or fibrosis.

### Claim 6 (depends on 2)

The method of claim 2, wherein the liver disorder is non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, steatosis, and/or fibrosis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is administered to the human subject orally.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is formulated as liquid, powder, tablet, paste, capsule, or gel.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering the composition to the human subject:
decreases inflammation;
increases liver total bile acids;
decreases primary bile acids; and/or
decreases free fatty acid concentration in liver bile acid.

### Claim 10 (depends on 1)

The method of claim 1, wherein administering the composition to the human subject decreases inflammation in the liver, macrophages, the intestine, and/or the lung.

### Claim 11

A method of treating acute respiratory distress syndrome, the method comprising administering to a human subject a therapeutically effective amount of a composition containing a tryptophan metabolite or a derivative thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the tryptophan metabolite contains indole 3-acetate or a derivative thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the tryptophan metabolite contains tryptamine or a derivative thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the tryptophan metabolite contains xanthurenic acid or a derivative thereof.

### Claim 15 (depends on 11)

The method of claim 11, wherein the acute respiratory distress syndrome is associated with an infection by severe acute respiratory syndrome coronavirus 2.

### Claim 16 (depends on 12)

The method of claim 12, wherein the acute respiratory distress syndrome is associated with an infection by severe acute respiratory syndrome coronavirus 2.

### Claim 17 (depends on 11)

The method of claim 11, wherein the composition is administered to the human subject orally.

### Claim 18 (depends on 11)

The method of claim 11, wherein the composition is formulated as liquid, powder, tablet, paste, capsule, or gel.

### Claim 19 (depends on 11)

The method of claim 11, wherein administering the composition to the human subject decreases inflammation.

### Claim 20 (depends on 11)

The method of claim 11, wherein administering the composition to the human subject decreases inflammation in the liver, macrophages, the intestine, and/or the lung.
